Report      Database

    Global Osteoporosis Market, Patients, Companies & Forecast

    Date: 24 Sep, 2015              Type: Life Science              Pages: 124

    Global Osteoporosis Market, Patients, Companies & Forecast
    • Electronic Access - Single User License
      $1,100.00
    • CD-ROM Mail Delivery
      $1,200.00
    • Hard-copy Mail Delivery
      $1,200.00
    • Electronic Access - Multi User License
      $1,800.00

    Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. Globally Osteoporosis is expected to be more than US$ 40 Billion market by 2019. China and India together have close to 80% of osteoporosis patients worldwide. Whereas this in case of hip fracture cases both the countries China and India have more than 60% patients. But when we study Osteoporosis in market terms then United States controls the highest market share followed by China and Japan. Amgen and Eli Lilly are two dominant players in Osteoporosis drugs market.

    This is the 2nd edition report on Osteoporosis by Renub Research. Report titled “Global Osteoporosis Market, Patients, Companies & Forecast” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 124 page report with 89 Figures and 8 Tables studies the Worldwide Osteoporosis market from 6 view points: 

    1)    Osteoporosis Patients & Forecast
    2)    Hip fracture Patients & Forecast
    3)    Osteoporosis Market & Forecast 
    4)    Country Wise Osteoporosis level of Awareness, Guidelines & Policy 
    5)    Country Wise Reimbursement of Medication 
    6)    Company Wise Osteoporosis Drugs Sales & Forecast  

    All the 10 Countries studied in the report are as follows 

    1)     India
    2)     China
    3)     Japan
    4)     Korea
    5)     Brazil
    6)     Russia
    7)     United Kingdom
    8)     France
    9)     Germany
    10)     United States

    Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019)

    1)    Merck 
    2)    Sanofi 
    3)    Novartis 
    4)    Eli Lilly
    5)    Amgen

    Data Sources 

    This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts. 

    Primary sources include industry surveys and telephonic interviews with industry experts. 

    Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

    1.    Executive Summary

    2.    Worldwide Osteoporosis Patients Population Analysis
    2.1    Worldwide Osteoporosis Patients Population (2010 – 2019) 
    2.2    Worldwide Hip Fracture Patients Population (2010 – 2019) 

    3.    Worldwide Osteoporosis Market (2010 – 2019) 

    4.    Worldwide Osteoporosis Share Analysis
    4.1    Worldwide Osteoporosis Patients Population Share (2010 – 2019) 
    4.2    Worldwide Hip Fracture Patients Population Share (2010 – 2019) 
    4.3    Worldwide Osteoporosis Market Share (2010 – 2019) 
    4.4    Worldwide Osteoporosis Drugs Company Market Share (2010 –   2019) 

    5.    India
    5.1    India Osteoporosis Patients Population (2010 – 2019) 
    5.2    India Hip Fracture Patients Population (2010 – 2019) 
    5.3    India Osteoporosis Market (2010 – 2019) 
    5.4    Level of Awareness
    5.5    Fracture Registries
    5.6    Government Policies
    5.7    Guidelines
    5.8    Reimbursement of Medication

    6.    China
    6.1    China Osteoporosis Patients Population (2010 – 2019) 
    6.2    China Hip Fracture Patients Population (2010 – 2019) 
    6.3    China Osteoporosis Market (2010 – 2019) 
    6.4    Level of Awareness
    6.5    Fracture Registries
    6.6    Government Policies
    6.7    Guidelines
    6.8    Reimbursement of Medication

    7.    Japan
    7.1    Japan Osteoporosis Patients Population (2010 – 2019) 
    7.2    Japan Hip Fracture Patients Population (2010 – 2019) 
    7.3    Japan Osteoporosis Market (2010 – 2019) 
    7.4    Level of Awareness
    7.5    Fracture Registries
    7.6    Government Policies
    7.7    Guidelines
    7.8    Reimbursement of Medication

    8.    Korea
    8.1    Korea Osteoporosis Patients Population (2010 – 2019) 
    8.2    Korea Hip Fracture Patients Population (2010 – 2019) 
    8.3    Korea Osteoporosis Market (2010 – 2019) 
    8.4    Level of Awareness
    8.5    Fracture Registries
    8.6    Government Policies
    8.7    Guidelines
    8.8    Reimbursement of Medication

    9.    Brazil
    9.1    Brazil Osteoporosis Patients Population (2010 – 2019) 
    9.2    Brazil Hip Fracture Patients Population (2010 – 2019) 
    9.3    Brazil Osteoporosis Market (2010 – 2019) 
    9.4    Level of Awareness
    9.5    Guidelines & Policy
    9.6    Reimbursement Policy

    10.    Russia
    10.1    Russia Osteoporosis Patients Population (2010 – 2019) 
    10.2    Russia Hip Fracture Patients Population (2010 – 2019) 
    10.3    Russia Osteoporosis Market (2010 – 2019) 
    10.4    Level of Awareness
    10.5    Government Policy
    10.6    Guidelines
    10.7    Reimbursement

    11.    United Kingdom
    11.1    United Kingdom Osteoporosis Patients Population (2010 – 2019) 
    11.2    United Kingdom Hip Fracture Patients Population (2010 – 2019) 
    11.3    United Kingdom Osteoporosis Market (2010 – 2019) 
    11.4    Guidelines
    11.5    Reimbursement Policy

    12.    France
    12.1    France Osteoporosis Patients Population (2010 – 2019) 
    12.2    France Hip Fracture Patients Population (2010 – 2019) 
    12.3    France Osteoporosis Market (2010 – 2019) 
    12.4    Guidelines
    12.5    Reimbursement Policy

    13.    Germany
    13.1    Germany Osteoporosis Patients Population (2010 – 2019) 
    13.2    Germany Hip Fracture Patients Population (2010 – 2019) 
    13.3    Germany Osteoporosis Market (2010 – 2019) 
    13.4    Guidelines
    13.5    Reimbursement Policy

    14.    United States
    14.1    United States Osteoporosis Patients Population (2010 – 2019) 
    14.2    United States Hip Fracture Patients Population (2010 – 2019) 
    14.3    United States Osteoporosis Market (2010 – 2019) 
    14.4    Policy
    14.5    Guidelines
    14.6    Reimbursement Policy

    15.    Growth Driver
    15.1    Widespread Vitamin D Deficiency & Low Calcium Intake
    15.2    Globally Increasing Ageing Population & Life Expectancy

    16.    Challenges
    16.1    Lack of Reimbursement / Other Restrictions for Reimbursement
    16.2    Limited Access of Diagnostic Tools & Low Levels of Public and Health Professional Awareness
    16.3    Lack of Government Osteoporosis Policy, Guidelines & National Health Priority in Asia Pacific Countries

    17.    Key Players Osteoporosis Drugs Sales & Forecast
    17.1    Merck Osteoporosis Drugs Sales (2010 – 2019) 
    17.2    Sanofi Osteoporosis Drugs Sales (2010 – 2019) 
    17.3    Novartis Osteoporosis Drugs Sales (2010 – 2019) 
    17.4    Eli Lilly Osteoporosis Drugs Sales (2010 – 2019) 
    17.5    Amgen Osteoporosis Drugs Sales (2010 – 2019) 

    List of Figures

    Figure 2–1: Worldwide – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 2–2: Worldwide – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 2–3: Worldwide – Distribution of Hip Fracture Risk in Men, 2012
    Figure 2–4: Worldwide – Distribution of Hip Fracture Risk in Women, 2012
    Figure 2–5: Worldwide – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 2–6: Worldwide – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019

    Figure 3–1: Worldwide – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 3–2: Worldwide – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 4–1: Worldwide – Osteoporosis Patients Population Share (Percent), 2010 – 2014
    Figure 4–2: Worldwide – Forecast for Osteoporosis Patients Population Share (Percent), 2015 – 2019
    Figure 4–3: Worldwide – Hip Fracture Patients Population Share (Percent), 2010 – 2014
    Figure 4–4: Worldwide – Forecast for Hip Fracture Patients Population Share (Percent), 2015 – 2019
    Figure 4–5: Worldwide – Osteoporosis Market Share (Percent), 2010 – 2014
    Figure 4–6: Worldwide – Forecast for Osteoporosis Market Share (Percent), 2015 – 2019
    Figure 4–7: Worldwide – Osteoporosis Drugs Company Market Share (Percent), 2010 – 2014
    Figure 4–8: Worldwide – Forecast for Osteoporosis Drugs Company Market Share (Percent), 2015 – 2019

    Figure 5–1: India – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 5–2: India – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 5–3: India – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 5–4: India – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 5–5: India – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 5–6: India – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 6–1: China – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 6–2: China – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 6–3: China – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 6–4: China – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 6–5: China – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 6–6: China – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 7–1: Japan – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 7–2: Japan – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 7–3: Japan – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 7–4: Japan – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 7–5: Japan – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 7–6: Japan – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 8–1: Korea – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 8–2: Korea – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 8–3: Korea – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 8–4: Korea – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 8–5: Korea – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 8–6: Korea – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 9–1: Brazil – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 9–2: Brazil – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 9–3: Brazil – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 9–4: Brazil – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 9–5: Brazil – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 9–6: Brazil – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 10–1: Russia – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 10–2: Russia – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 10–3: Russia – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 10–4: Russia – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 10–5: Russia – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 10–6: Russia – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
    Figure 10–7: Russia – Level of Awareness (Percent), 2010

    Figure 11–1: United Kingdom – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 11–2: United Kingdom – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019. 
    Figure 11–3: United Kingdom – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 11–4: United Kingdom – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 11–5: United Kingdom – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 11–6: United Kingdom – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 12–1: France – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 12–2: France – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 12–3: France – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 12–4: France – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 12–5: France – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 12–6: France – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 13–1: Germany – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 13–2: Germany – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 13–3: Germany – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 13–4: Germany – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 13–5: Germany – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 13–6: Germany – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 14–1: United States – Osteoporosis Patients Population (Thousand), 2010 – 2014
    Figure 14–2: United States – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
    Figure 14–3: United States – Hip Fracture Patients Population (Thousand), 2010 – 2014
    Figure 14–4: United States – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
    Figure 14–5: United States – Osteoporosis Market (Million US$), 2010 – 2014
    Figure 14–6: United States – Forecast for Osteoporosis Market (Million US$), 2015 – 2019

    Figure 15–1: Worldwide – Ageing Population & Forecast (Million), 2010 – 2050
    Figure 15–2: Worldwide – Life Expectancy (Year), 1990, 2000 & 2012

    Figure 17–1: Merck – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
    Figure 17–2: Merck – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
    Figure 17–3: Sanofi – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
    Figure 17–4: Sanofi – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
    Figure 17–5: Novartis – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
    Figure 17–6: Novartis – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
    Figure 17–7: Eli Lilly – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
    Figure 17–8: Eli Lilly – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
    Figure 17–9: Amgen – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
    Figure 17–10: Amgen – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019

     

    List of Tables

    Table 5–1: India – Osteoporosis Treatments & Respective Reimbursement Status, 2013

    Table 6–1: China – Osteoporosis Treatments & Respective Reimbursement Status, 2013

    Table 7–1: Japan – Osteoporosis Treatments & Respective Reimbursement, 2013

    Table 8–1: Korea – Osteoporosis Treatments & Respective Reimbursement, 2013

    Table 11–1: United Kingdom – Available Medical Interventions & Reimbursement Policies, 2013

    Table 12–1: France – Available Medical Interventions & Reimbursement Policies, 2013

    Table 13–1: Germany – Available Medical Interventions & Reimbursement Policies, 2013

    Table 16–1: Asia Pacific – Status of Osteoporosis in NHP & Guidelines Availability, 2013

    • Description
      Price
    • Chapter 1 & 2     Pages : 8
      $250
    • Chapter 3     Pages : 2
      $150
    • Chapter 4     Pages : 11
      $350
    • Chapter 5     Pages : 8
      $125
    • Chapter 6     Pages : 9
      $125
    • Chapter 7     Pages : 8
      $125
    • Chapter 8     Pages : 7
      $125
    • Chapter 9     Pages : 7
      $125
    • Chapter 10     Pages : 7
      $125
    • Chapter 11     Pages : 6
      $125
    • Chapter 12     Pages : 6
      $125
    • Chapter 13     Pages : 6
      $125
    • Chapter 14     Pages : 6
      $125
    • Chapter 15     Pages : 4
      $100
    • Chapter 16     Pages : 3
      $100
    • Chapter 17     Pages : 10
      $275

    Related Products

    • Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast


      Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast
      Renub Research report titled "Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast" provides a comprehensive analysis of the current state of the market and likely future evolution over the next 5 years....
      Date: 05 Aug, 2016
      Type: Company Analysis
      Pages: 21
      Price: $350.00
    • Global Spinal Fusion Market, Procedure Volume and Forecast


      Global Spinal Fusion Market, Procedure Volume and Forecast
      Spinal fusion is multi Billion dollar market with huge future potential. In 2014 Spinal fusion market was more than US$ 20 Billion. Germany, United States and China are the top three markets (not in the same chronological order) worldwide. In 2014, Spinal fusion procedure volume has crossed over 1 M...
      Date: 23 Nov, 2015
      Type: Drugs & Pharmaceuticals
      Pages: 62
      Price: $1,000.00
    • Global Osteoporosis Market & Drugs Analysis 2010 - 2015


      Global Osteoporosis Market & Drugs Analysis 2010 - 2015
      Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture. Global osteoporosis market is expected to r...
      Date: 01 Sep, 2011
      Type: Life Science
      Pages: 72
      Price: $950.00